Novo Nordisk’s Bold Strategy: A Game-Changer for Obesity Treatment Access?
Novo Nordisk’s stock rises 4%, outperforming the S&P 500’s 1.1% gain, following the NovoCare Pharmacy service announcement. The company offers Wegovy, a best-selling obesity medication, directly to patients at a reduced cost of $499 per month. This initiative aims to increase healthcare
